Table 1 Patient demographics, clinical presentation, and outcomes.

Gestational age at birth(weeks)

Term (< 37)

29/34 (85.3%)

Moderate-to-late preterm (32–37)

4/34 (11.8%)

Very preterm (> 32)

1/34 (2.9%)

Sex

Male

21/34 (61.8%)

Female

13/34 (38.2%)

Mode of delivery

Vaginal

29/34 (85.3%)

Cesarean delivery

5/34 (14.7%)

Birth weight

< 2.5 kg

7/34 (20.1%)

> 2.5 kg

27/34 (79.4%)

Imaging indication

Asphyxia

7/34 (20.1%)

Jaundice

14/34 (41.2%)

Cyanosis

5/34 (14.7%)

Fever

3/34 (8.8%)

Seizure

1/34 (2.9%)

Dyspnea

4/34 (11.8%)

APGAR score at 1 min

7.61 (range,1–10)

APGAR score at 5 min

9 (range, 3–10)

APGAR score at 10 min

9.76 (range, 4–10)

APGAR score is unknown

8/34

Coagulation abnormalities (first 7 postnatal days)

AT3 (80–120%)

25/32 56.16% (range, 23–79%)

FDP (0–5 μg/ml))

16/32 16.65 μg/ml (range, 5.92–40.69 μg/ml)

D-D (0–0.5 μg/ml))

12/32 6.41 μg/ml (range, 0.76–25.56 μg/ml)

PT (10–14 s)

10/32 20.13 s (range, 14.6–31.0 s)

APTT (28–48 s)

8/32 55.96 s (range, 48.8–68.8 s)

FIB (170–450 mg/dL)

8/32 372.75 mg/dL (range, 41–683 mg/dL)

TT (14-20 s)

5/32 28.28 s (range,21.9–35.2 s)

INR (0.8–1.5)

2/32 2.85 (range, 2.72–2.97)

Age at onset of symptoms

11d (range, 5-28d)

Age at most recent follow-up in months, median

29 (3–62)

outcome

Died

1/29

Abnormality at most recent follow-up

Dyskinesia

7/28 (25.0%)

Developmental retardation

5/28 (17.9%)

No neurologic deficits

16/28 (57.1%)